The studies from COGS included in this collection nearly double the number of common genetic variants significantly associated with susceptibility to breast, ovarian and prostate cancers. While this set of cancer-associated variants contributes substantially to disease heritability, these studies also predict that an additional large number of common variants not yet associated with disease have the potential to explain the majority of the familial recurrence of these cancers.
The findings from ten of the coordinated COGS papers are presented in Table 1 . Of the six published in this issue of Nature Genetics, four involved GWAS meta-analysis and validation using iCOGS data 1-4 , and one entailed fine mapping and functional analysis of the TERT region (5p15.33) in relation to mean telomere length and the risk of breast and ovarian cancers 5 . These studies detected new loci associated with overall risk of breast cancer (n = 41) 1 , ovarian cancer (n = 2) 3 and prostate cancer (n = 23) 4 . A few additional loci were identified specifically for risk of estrogen receptor (ER)-negative breast cancer (n = 4) 2 and for serous ovarian cancer (n = 1) 3 . In the TERT region, several distinct SNP associations for breast cancer, ovarian cancer and telomere length were evident, underscoring the complex interplay of common variants across this genomic region in carcinogenesis and telomere maintenance 5 . Breast cancer. There have been 27 previously published loci associated with breast cancer (P < 5 × 10 -8 ). All but four of these showed clear evidence of association with overall breast cancer risk in the COGS data. Common variants at 41 new loci were associated at genome-wide statistical significance (P < 5 × 10 -8 ) with overall breast cancer risk (Nat. Genet. doi:10.1038/ng. 2563 , 27 March 2013 , and SNPs at a further 4 loci were associated specifically with ER-negative breast cancer ( Table 1 in Nat. Genet. doi:10.1038 /ng.2561 , 27 March 2013 . The variant at one of the ER negative-specific loci was also associated with breast cancer risk in BRCA1 mutation carriers at P < 5 × 10 -8 (PLoS Genet. 9, e1003212, 2013) , and a further independent locus was associated specifically with breast cancer risk in BRCA2 mutation carriers (PLoS Genet. 9, e1003173, 2013) . Fine-mapping studies identified three independent loci in the previously reported region at 11q13 (Am. J. Hum. Genet. doi:10.1016 /j.ajhg.2013 .01.002, 27 March 2013 and two additional independent breast cancer susceptibility loci in a region at 5p15 ( Table 2 in Nat. Genet. doi:10.1038 /ng.2566 , 27 March 2013 . These findings bring the total number of breast cancer susceptibility loci to 76. Of the 27 previously established breast cancer loci, 26 were included on the iCOGS array (rs2284378 at 20q11 was not selected), and consistent evidence of association with overall or ER-negative breast cancer risk (P < 1.0 × 10 -4 ) was observed for all but 2 of these (Nat. Genet. doi:10.1038 /ng.2563 , 27 March 2013 and Nat. Genet. doi:10.1038 /ng.2561 , 27 March 2013 . Weaker evidence for association was found for rs1045485 in CASP8 and rs2380205 at 10p15.
Ovarian cancer. Four loci have previously been reported to be associated with ovarian cancer at genome-wide significance. These were all confirmed by the COGS data, as were two other loci previously reported close to genome-wide significance. Three new ovarian cancer susceptibility loci were identified at genome-wide significance ( Table 2 in Nat. Genet. doi:10.1038 /ng.2564 , 27 March 2013 ; two were associated with overall risk, and one was associated specifically with risk of the serous subtype.
A more detailed analysis of the association at 17p12 reported by Pharoah et al. is reported in Shen et al. (Table 1 of Nat. Commun. doi:10.1038 /ncomms2629, 27 March 2013 . Of particular interest was the finding that different loci in the same region were associated with the serous and clear-cell subtypes. Variants at the 17q21.31 locus were associated with ovarian cancer risk in BRCA1 mutation carriers (PLoS Genet. 9, e1003212, 2013) and also in BRCA2 mutation carriers (PLoS Genet. 9, e1003173, 2013 2566 , 27 March 2013 . Finally, an additional locus was associated with ovarian cancer risk for BRCA1 mutation carriers only (PLoS Genet. 9, e1003212, 2013) . These findings bring the total number of ovarian cancer susceptibility loci to 12. Percentage of familial relative risk due to high-or moderate-penetrance alleles. For genes included, see Figure 1 . f For breast cancer, the estimated contribution to FRR of all SNPs selected for the iCOGS array on the basis of evidence of association in a meta-analysis of nine breast cancer GWAS in women of European ancestry was 28%. g Assuming FRR for ER-negative breast cancer is also 2. h Includes breast or ovarian cancer susceptibility loci in the general population shown to modify cancer risk in BRCA1 or BRCA2 mutation carriers (at P < 0.05) (PLoS Genet. 9, e1003212, 2013 and PLoS Genet. 9, e1003173, 2013 Table 1 ). For breast cancer only, other iCOGS estimated refers to the estimated contribution of all other SNPs on the iCOGS array that were selected for replication of GWAS2.
Fine-mapping efforts in COGS
One of the major aims of the COGS project was the fine mapping of previously identified susceptibility loci for breast, ovarian and prostate cancers by genotyping a very dense panel of markers, drawn from the 1000 Genomes Project dataset across these regions. The COGS project included the fine mapping of over 50 selected genomic regions to identify variants more strongly associated with the disease than those reported in the original GWAS, as well as additional associated variants that may contribute to heritability. The fine mapping of two regions, at 5p15 and 11q1, has been reported in detail in these publications. These analyses suggest that the fine mapping of susceptibility regions can be productive in identifying further susceptibility variants that contribute to overall genetic risks for these cancers.
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer Our comprehensive examination of the TERT locus has answered some long-standing questions and raised several new ones. We have identified two independent regions associated with telomere length in leukocyte DNA; these provide definitive evidence for genetic control of telomere length by common TERT variants. For rs2736108, the most significant SNP in promoter peak 1, the minor allele is associated with a 1.7% increase in telomere length. This is equal to a telomere length change of ~60 bp, which, because telomere length decreases by approximately 19 bp per year 50 , is equivalent in magnitude to an age difference of 3.1 years. We estimate that rs2736108 explains 0.08% of the variance in telomere length in men and 0.06% of the variation in women. SNPs in peak 2 have a stronger effect on telomere length, with each additional A (minor) allele of rs7705526 associated with a 2.6% increase. This is equal to a ~90 bp change in telomere length and, correspondingly, to 4.7 years of age. We estimate that rs7705526 explains 0.31% of the variance in telomere length in men and 0.16% of the variance in women. 
Heritability estimates in COGS studies

Additional heritability
As shown in Table 1 , the estimated proportion of the familial risk attributable to the total currently known set of susceptibility loci for these three cancers (including previous associations and those identified in the current COGS publications), ranges from ~4% for ovarian cancer to ~31% for prostate cancer. However, there are many more SNPs that show nominally significant associations to each cancer but that do not reach the established genome-wide significance threshold for association in these publications. This is shown most clearly for breast cancer, with Michailidou et al. finding that there is a clear excess of significant associations among all SNPs genotyped on the iCOGS array that were selected from GWAS, even at levels of significance below the conventional genome-wide significance threshold. Further support for the existence of a much larger number of breast cancer susceptibility loci is provided by the finding that the associations in the iCOGS replication data sets tend to go in the same direction as those in the GWAS from which the SNPs were selected, even for SNPs with associations below the genome-wide significance threshold.
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However, the overall excess of significant associations for SNPs selected from the breast cancer GWAS for genotyping in the iCOGS stage suggests that a much larger number of loci contribute to susceptibility, although they did not have associations reaching genome-wide levels of significance in the current study.
To assess this hypothesis more formally, we identified a set of 10,668 SNPs selected from the GWAS that were uncorrelated (r 2 < 0.1 between any pair). Of these, the estimated OR was in the same direction as in the combined GWAS for 5,918 SNPs and in the opposite direction for 4,750 SNPs. Assuming that SNPs with effects in opposite directions are not associated with risk, an estimated 1,168 loci selected from the GWAS are associated with risk. However, this is an underestimate because weakly associated SNPs might have effects in opposite directions in the two stages.
A similar finding was seen for prostate cancer, in comparing the direction of association for SNPs on the iCOGS array and those for the same SNPs in the GWAS dataset. Once again, the direction of effect in the iCOGS replication data set was in the same direction for over half of the selected SNPs, suggesting that there may be a much larger number of prostate cancer susceptibility loci. The overall inflation in the test statistics for those SNPs selected for GWAS replication suggests that the number of susceptibility loci may be much larger. To address this possibility more formally, we identified 22,662 SNPs selected for replication of the prostate cancer GWAS that were uncorrelated (r 2 < 0.1 for any pair) and examined the directions of the estimated ORs in the iCOGS replication data set. The estimated effects were in the same direction as in the GWAS for 12,278 SNPs and in the opposite direction for 10,384 SNPs. On the basis of this analysis, 1,894 (95% CI = 1,600-2,188) selected SNPs reflect true associations with disease.
Michailidou, K., Hall, P., Gonzalez-Neira, A., Ghoussaini, M., Dennis, J. et al. doi:10.1038 Dennis, J. et al. doi:10. /ng.2563 As an alternative approach, we fitted the distribution of z scores for the iCOGS stage, aligned to the direction of the effect in the GWAS, as a mixture of two normal distributions representing those SNPs that were or were not associated with disease ( Fig. 2 and Online Methods) 58 . On the basis of the posterior probabilities from this analysis, an estimated 92% of loci (n = 9,815) were associated with breast cancer risk (95% CI = 85-100%), and these contributed approximately 18% of the familial risk of breast cancer. It should be noted, however, that the large majority of the loci had very small individual effects on risk: for example, the estimated OR was >1.05 for only 10 loci, and 920 loci had an estimated OR of >1.02. When taking into account effects from the previously known loci, these analyses suggest that ~28% of familial risk is explained by common variants selected for iCOGS, of which ~14% can be explained by the 67 established loci (with a further ~20% due to higher penetrance loci).
What we have learned
The current collection of COGS publications together demonstrate that (i) the contribution of common SNPs to the heritability of breast, ovarian and prostate cancers is substantial, (ii) the number of SNPs associated with each disease is very large, at least several thousand, and (iii) the contribution of the SNPs not yet definitively associated with disease is probably much greater than those that have been identified so far and may explain the majority of the familial aggregation of these diseases. The lower contribution of common SNPs to familial risk identified for ovarian cancer may be a reflection of the smaller sample size available, as the effect sizes for the known SNPs are comparable to those for breast cancer.
The above analyses are based on an assumption that the disease-associated variants combine multiplicatively. If there are interactions between loci or between genetic loci and environmental or lifestyle risk factors, the contribution of common variants could be greater. In addition, rare variants that are not captured on the iCOGS array may confer higher risks and explain additional heritability. Such rare susceptibility variants have been identified previously for all these cancers (Fig. 1) . These variants are located in genes such as BRCA1 and BRCA2 that are associated with high risk, identified through linkage analysis and positional cloning, in genes that confer more moderate risk such as PALB2, identified through sequencing of candidate genes in case-control studies. . These results suggest that the contribution of common SNPs to the heritability of these cancers, although substantial overall, is smaller at younger ages and, hence, that the search for rarer disease-causing variants should focus on younger cases.
Heritability estimates explained
The heritability of a trait is defined as the proportion of the phenotypic variance that can be attributed to genotype. For a disease trait, the analysis is usually conducted using an underlying continuous liability, whereby individuals are assumed to be affected if they exceed a certain liability threshold. The heritability then refers to the heritability on the liability scale, rather than the heritability of the observed trait values (Nat. Rev. Genet. 9, [255] [256] [257] [258] [259] [260] [261] [262] [263] [264] [265] [266] 2008) .
Often a more direct and useful measure, however, is the proportion of the observed FRR (denoted λ) that can be attributable to SNPs or other genetic variants.
For a locus with a log-additive association with risk, the FRR to the offspring of a case is given by where p k is the frequency of the risk allele, q k = 1 -p k and r k is the per-allele relative risk.
Assuming that the loci combine multiplicatively and are not in linkage disequilibrium, the combined effect of all loci is given by where the product is across all loci. The proportion of the familial relative risk attributable to the SNPs, on a log scale, is then given by log(λ T )/log(λ P ), where λ P is the familial relative risk observed in epidemiological studies. λ P is 2-3-fold for breast, ovarian and prostate cancers.
Another way of expressing this is that, under a simple polygenic model, the observed FRR where is the variance of the underlying polygenic component. The proportion of the familial risk explained is then given by where is the proportion of the polygenic variance explained by SNP k and b k = log(l k ) is the per-allele log(relative risk).
